Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Terminated 3Completed 2Suspended 1

Sponsor Class

OTHER 9INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2CNS 2Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Glioblastoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × TPI-287 × Clear all
NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Cortice Biosciences, Inc.

Phase 1/2 Suspended
92 enrolled
CNS

Glioblastoma

NCT02047214 2018-01-31

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Cortice Biosciences, Inc.

Phase 2 Terminated
17 enrolled
CNS

Glioblastoma

NCT00479635 2014-01-22

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Cortice Biosciences, Inc.

Phase 2 Terminated
26 enrolled
Genitourinary

Prostatic Neoplasms

NCT00553813 2014-01-22

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

Cortice Biosciences, Inc.

Phase 2 Terminated
23 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00113724 2009-06-04

Study of TPI 287 in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
48 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

NCT00256191 2007-10-15

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
45 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡